Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

Abstract Introduction In 2016, SB4 (Benepali®) became the first etanercept (ETN) biosimilar to obtain marketing authorisation in Europe. Despite robust analytical and clinical comparisons, outstanding questions remain on SB4 use in routine practice. Methods A systematic search for publications on re...

Full description

Bibliographic Details
Main Authors: Hans C. Ebbers, Burkhard Pieper, Amine Issa, Janet Addison, Ulrich Freudensprung, Mourad F. Rezk
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-08-01
Series:Rheumatology and Therapy
Subjects:
Benepali
Biosimilar
ETN
Nocebo
Persistence
Real-world evidence
Online Access:http://link.springer.com/article/10.1007/s40744-019-00169-4

Internet

http://link.springer.com/article/10.1007/s40744-019-00169-4

Similar Items